Overview of Dr. Yu
Dr. Helena Yu is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from University of Michigan Medical School and has been in practice 10 years. She is one of 503 doctors at Memorial Sloan Kettering Cancer Center and one of 87 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.
Office
530 East 74th Street
New York, NY 10021
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
University of Michigan Medical SchoolClass of 2007
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2020 - 2025
NY State Medical License 2010 - 2025
PA State Medical License 2007 - 2010
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer Start of enrollment: 2004 Aug 01
- Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Start of enrollment: 2013 Oct 15
- Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Emerging importance of HER3 in tumorigenesis and cancer therapy.Joan T Garrett, Salomon Tendler, Wasim Feroz, Mary Kate Kilroy, Helena Yu
Nature Reviews. Clinical Oncology. 2025-03-14 - A Podcast Discussion on the Intracranial Efficacy of Antibody-Drug Conjugates in Patients with EGFR-Mutated NSCLC with Brain Metastases.Melissa L Johnson, Jessica J Lin, Adrienne Boire, Melin J Khandekar, Helena A Yu
Oncology and Therapy. 2025-03-01 - REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients withexon 20 insertion-mutated NSCLC.John V Heymach, Helena A Yu, Benjamin Besse, Ying Cheng, Daniel Sw Tan
Future Oncology. 2025-02-01
Journal Articles
- Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung CancersHelena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAlexander I Spira, Helena A Yu, Clinical Lung Cancer
- YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical GenomicsEmmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences
Lectures
- A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.2019 ASCO Annual Meeting - 6/1/2019
- Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018
Press Mentions
New Targeted Therapy Strategies for Addressing Non-Small Cell Lung Cancer Metastatic DiseaseMarch 24th, 2025- Clinical Trials of New Stereotactic Radiosurgery Strategies for Lung Cancer Brain MetastasesMarch 24th, 2025
- In the US, Young and Middle-Aged Women Are Being Diagnosed with Lung Cancer at Higher Rates Than MenNovember 25th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
